ABSTRACT
The complement system, along with its intricate network, constitutes a vital component of the innate immune response, playing a pivotal role in defending the host against invading pathogens. While it is essential for maintaining immune homeostasis, dysregulation of this system can lead to significant pathological consequences: deficiencies in complement components increase susceptibility to infections, whereas excessive activation causes inflammatory tissue damage. Through its diverse functions and regulatory mechanisms, including but not limited to cytolytic effects, opsonophagocytosis, induction of inflammatory responses, and facilitation of antigen presentation, the complement system can independently or synergistically eliminate pathogens with high specificity and efficiency. In response to this robust immune defense strategy, pathogens have evolved a range of sophisticated evasion and resistance mechanisms to counteract the lethal effects of complements. In-depth research into these complement-pathogen interactions enhances our understanding of disease pathogenesis and progression, providing vital theoretical foundations and potential targets for novel therapeutics.
KEYWORDS: Complement system, complosome, interactions, infection and anti-infection, vaccine strategies
Introduction
During the late 19th and early 20th centuries, Jules Bordet, a Belgian scientist, identified a heat-sensitive component in fresh serum that facilitated the bacteriolytic activity of specific antibodies. Concurrently, German scientist Paul Ehrlich independently made a similar observation and postulated that this factor was both necessary and sufficient for antibodies to mediate cytolytic effects, coining the term “Complement” (C) to describe it [1]. Subsequent research led to the identification and characterization of numerous complement components, culminating in the conceptualization of the complement system. Initially regarded as an evolutionarily ancient and essential element of innate immunity, the complement system served as a primary defense mechanism against pathogenic invasions [2]. However, advancements in research have prompted a reevaluation of this system, uncovering its broader and more pivotal roles in biological processes [3].
The complete complement system comprises approximately 50 proteins that form an intricate network involving fluid-phase, cell surface-associated, and intracellular components. These proteins serve as pattern recognition molecules, protease/convertase enzymes, regulators, and signaling receptors to collectively regulate immune surveillance and maintain tissue homeostasis [4]. Under physiological conditions, complement components exist in inactive forms within plasma and on cellular surfaces. Upon the recognition of pathogens or foreign substances, specific proteases within the system cleave key proteins to initiate complement cascades [5]. Three distinct activation pathways (the classical pathway, alternative pathway, and lectin pathway) converge to generate C3 convertase, a proteolytic enzyme complex that cleaves C3 into C3a and C3b. This proteolytic event triggers the sequential activation of downstream complement components, facilitating multiple immune functions: opsonization of microbial invaders via C3b coating, pro-inflammatory responses mediated by anaphylatoxins C3a and C5a, and direct pathogen lysis through the formation of the membrane attack complex (MAC, C5b-9). In addition to the above functions, the complement system plays a crucial role in integrating both innate and adaptive immunity [6]. While the complement cascade has been extensively delineated in multiple studies [7], excessive activation of this system can cause inflammatory tissue damage. Therefore, stringent regulation by soluble and membrane-bound regulators is essential to ensure effective pathogen elimination while preserving tissue integrity [1].
Research conducted over the past decade has significantly expanded our understanding of the operational mechanisms and functional domains of the complement system. Importantly, these functions extend far beyond their traditional roles in the blood and liver, encompassing diverse systems including the gastrointestinal tract, brain, nervous system [8], and even intracellular compartments within various cell types. These advancements can be broadly categorized by their functional focus as follows: (1) Antimicrobial defense in barrier tissues: For instance, Hu et al. demonstrated a novel bacterial evasion strategy whereby Helicobacter pylori utilizes L-lactate to escape complement-mediated attack, thereby facilitating gastric colonization. This finding specifically highlights the critical antimicrobial role of complement within the gastric environment [9]. In addition, Wu et al. further elucidated how the gut microbiota shapes local complement activity, delineating mechanisms through which microbiota-induced intestinal complement not only combats pathogens but also protects commensal bacteria [10]. (2) Non-infectious physiological and pathological roles: Extending beyond infection contexts, Simon et al. broadened this scope by demonstrating the presence of active complement components within intracellular compartments. Their work provided a comprehensive comparison between plasma-circulating and intracellularly active complements, revealing a novel operational landscape [11]. Moreover, Suzanne et al. elucidated significant roles for complement within the central nervous system, highlighting its contributions to neuroprotection, neuronal plasticity, and neuroinflammation [12]. Collectively, this body of research underscores the remarkable functional diversification of the complement system across multiple physiological compartments.
The complement system employs a series of mechanisms to detect and eliminate pathogens, thereby protecting the host from life-threatening infections [13]. In response, pathogens have evolved sophisticated molecular strategies to subvert, evade, and manipulate complement-mediated immune responses. Recent studies have identified certain non-classical virulence proteins that contribute to pathogenicity. For example, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a crucial enzyme in glycolysis, has been shown to bind human C1q and inhibit the activation of the classical pathway (CP), allowing Streptococcus to evade complement attack [14]. This finding indicates that beyond traditional virulence factors, additional pathogen-derived proteins may play auxiliary roles in facilitating infection and promoting immune evasion. With the escalating challenge of antibiotic resistance and the global implementation of “antibiotic reduction and substitution” policies, it has become increasingly imperative to comprehend the mechanisms underlying pathogen invasion and immune evasion. This review synthesizes fundamental concepts and recent advancements in complement biology, with a particular emphasis on the complex interactions between the complement system and pathogens. Rather than merely cataloging individual case studies, this work integrates contemporary research to elucidate the dynamic interplay between pathogens and the complement system, along with the underlying molecular mechanisms. These insights may hold significant implications for future strategies in treating infectious and inflammatory diseases.
The consequences of dysregulation in the complement system and corresponding countermeasures
There exists a delicate balance between the complement system and autoimmunity. Both excessive and insufficient activation of the complement cascade can disrupt host defense mechanisms and inflammatory responses, potentially leading to autoimmune diseases [15]. On one hand, deficiencies or dysfunctions in complement factors can impair immune responses, resulting in recurrent bacterial infections or autoimmune diseases such as systemic lupus erythematosus (SLE) [16]. On the other hand, defects or dysfunctions in complement regulatory proteins may lead to excessive immune activation, causing uncontrolled inflammation and tissue damage [17]. This dysregulation has been associated with various diseases including paroxysmal nocturnal hemoglobinuria (PNH), hereditary angioedema, and atypical hemolytic uremic syndrome (aHUS) [18].
Increased risk of infection due to complement deficiency
Complement deficiency can be classified into primary and secondary deficiencies based on their underlying cause. Primary complement system deficiencies are genetically determined [19], whereas secondary complement deficiencies arise from excessive activation and subsequent depletion of complement components.
Generally, primary complement deficiencies are mostly inherited in an autosomal recessive manner. However, C1 inhibitor deficiency, which impairs a key regulator of the classical pathway initiation, follows an autosomal dominant inheritance pattern. In contrast, properdin deficiency, which affects a crucial stabilizing protein for the alternative pathway C3 convertase, is inherited in an X-linked recessive manner. Furthermore, deficiencies in mannose-binding lectin (MBL, a pattern recognition molecule initiating the lectin pathway) and coagulation factor I (FI, an essential protease that inactivates C3b to control all pathways) exhibit autosomal codominant inheritance [20]. Deficiencies in various complement components have been linked to respiratory infections and sepsis caused by pathogenic microorganisms [21]. Clinical studies have shown that patients with C3 deficiency are particularly vulnerable to infections caused by Streptococcus pneumoniae (S. pneumoniae), Haemophilus influenzae [22], and Neisseria species [15] from birth. Additionally, individuals with a heterozygous deficiency of complement factor D (CFD, a serine protease required for alternative pathway activation) demonstrate impaired activation of the alternative pathway (AP), resulting in a reduced rate of complement activation which leads to uncontrolled proliferation of Neisseria meningitidis (N. meningitidis) within the bloodstream [23].
Complement deficiency not only heightens susceptibility to pathogenic bacteria but also increases the risk of developing autoimmune diseases, including SLE, glomerulonephritis, and vasculitis (Table 1). C1q has been shown to bind apoptotic cells and cellular debris, thereby preventing them from acting as self-antigens. In the absence of C1q binding, apoptotic cells may elicit autoimmune responses, contributing to the onset of diseases like SLE [20]. Furthermore, deficiencies in early components of the classical pathway (C1q, C1r, C1s, C4, and C2) can impair the formation of C3b and consequently diminish the clearance of immune complexes [27]. These findings highlight that the complement system plays a critical role not only in infection prevention but also in maintaining immune homeostasis by regulating inflammatory processes, managing aberrant cells, and controlling apoptotic cell fate and autophagy.
Table 1.
Causes and clinical manifestations of complement dysregulation.
| Classification | Mechanism Description | Clinical Manifestations and Consequences | References |
|---|---|---|---|
| Primary Complement Deficiency | Genetic mutations lead to congenital deficiencies or dysfunction of essential complement components (e.g. C1, C2, C3, factor D) or regulatory proteins (e.g. CD55, CD59). | Reduced ability to eliminate pathogens (e.g. Neisseria, Streptococcus pneumoniae), resulting in recurrent infections. | [1,2,20,22–26] |
| Insufficient activation of the classical, alternative, and lectin pathways leads to impaired immune cascade responses. | Inadequate clearance of immune complexes may potentially trigger autoimmune phenomena, such as SLE or glomerulonephritis. | ||
| Secondary Complement Deficiency | Persistent hyperactivation of the complement system due to severe infection, chronic inflammation, or specific pharmacological interventions, leads to the excessive consumption of essential complement components. | Temporary or long-term impairment of immune defense, increasing the risk of secondary infections. | [16–18,21] |
| Environmental factors or inflammatory mediators disrupt the synthesis and stability of complement components, leading to functional deficiencies. | Accompanied by persistent inflammation, which further leads to organ dysfunction, including conditions such as sepsis and localized inflammatory damage. | ||
| Autoimmune-mediated Aberrant Activation | The body produces autoantibodies targeting complement components (e.g. C3b) or regulatory proteins, disrupting the normal negative feedback regulation. This disruption results in prolonged activation of the complement system. | Induces systemic or localized inflammation, immune complex deposition, and target organ damage, which may lead to the development of systemic autoimmune diseases such as lupus nephritis and rheumatic disorders. | [3,15,27] |
| Pathogen-induced Aberrant Activation | Some pathogens utilize surface proteins or secretions (e.g. LPS, GAPDH, and other outer membrane proteins) to directly interact with complement components (e.g. C1q), triggering or enhancing local complement activation. | Excessive localized or systemic activation of the complement system can result in a cytokine storm and subsequent damage to host tissues | [4,7,9,14,19,28–31] |
| Pathogens manipulate the regulation of complement systems to evade immune responses. | Causes significant complications related to severe infections, including pneumonia, sepsis, and multiple organ dysfunction; accelerates the progression of the disease. | ||
| Deficiency of Complement Regulatory Proteins | Deficiency or dysfunction of membrane-bound complement regulatory proteins (e.g. CD55, CD59) disrupts the normal inhibitory barriers, resulting in an inability to regulate complement activation effectively. | Autoimmune attack on self-cells, commonly manifesting as hemolytic anemia, exemplified by conditions such as PNH. | [32–35] |
| Failure to timely terminate complement activation, resulting in an attack on self-cells. | Associated with complications arising from localized inflammation and the formation of microthrombi. |
The incidence of primary complement deficiencies is relatively low, whereas secondary complement deficiencies are more prevalent [15]. Any pathological process that triggers the activation of the complement cascade can result in complement depletion. Clinically, patients with autoimmune diseases and those receiving immunosuppressive therapy exhibit significantly reduced resistance to common pathogens, rendering them highly susceptible to infections such as S. pneumoniae respiratory infections, Escherichia coli (E. coli) urinary tract infections, and Staphylococcus aureus (S. aureus)-induced skin and soft tissue infections [15]. In laboratory studies, Dahmani et al. reported that mice deficient in C3 or C1q exhibited a significantly increased susceptibility to Rickettsia infection compared to wild-type (WT) C57BL/6 controls. This heightened susceptibility was correlated with elevated bacterial burdens across multiple tissues and a reduced expression of immune activation markers [36].
In contrast to the adverse effects typically associated with complement deficiencies, González-Espinoza et al. reported that complement depletion enhances Brucella abortu clearance in mice [37]. Their study demonstrated that complement-depleted mice infected with an equivalent dose of B. abortus exhibited higher survival rates, accelerated bacterial clearance in the spleen, and elevated serum levels of proinflammatory cytokines (notably IFN-γ) compared to immunocompetent controls. The authors propose that Brucella exploits complement as an immunomodulatory tool: initial low-level activation of the complement system recruits polymorphonuclear neutrophils (PMNs), which subsequently suppress T-helper 1 (Th1) responses through various mechanisms, including the secretion of IL-10. Depletion of complement alleviates this suppression, thereby enabling a Th1-dominated immunity response capable of efficiently eliminating bacteria [37]. Although these findings are currently confined to murine models, they suggest that complement functions as a novel “immune checkpoint” during chronic intracellular infections by modulating host immunity. This underscores the therapeutic potential of regulating complement for combating intracellular pathogens and warranting further investigation.
Tissue damage induced by excessive complement activation
Complement-mediated effects are essential for host defense against pathogenic infections. However, during severe infections such as sepsis, aberrant complement activation can exacerbate disease severity [20]. Uncontrolled complement activation may overwhelm the protective functions of complement regulatory factors, potentially resulting in widespread tissue damage within the host [38].
Genetic defects in complement regulatory proteins can lead to uncontrolled complement activation (Table 1). A study conducted by Fakhouri et al. identified a significant association between aHUS and mutations in genes encoding complement regulatory protein, including at least five complement genes: CFH, C3, CFI, CFB, and MCP [25]. In clinical practice, most cases of hemolytic uremic syndrome (HUS) are attributed to Enterohemorrhagic E. coli (EHEC) infections, however, a smaller proportion result from infections with non-EHEC pathogens such as S. pneumoniae, Pseudomonas aeruginosa (P. aeruginosa), influenza A virus, and human immunodeficiency virus (HIV). In cases of severe infection where complement activation occurs, and if mutated complement regulatory proteins fail to control this activation, it can lead to more severe manifestations of aHUS [26] and contribute to kidney injury [25].
Individuals co-infected with influenza virus and methicillin-resistant S. aureus (MRSA) exhibit significantly increased morbidity and mortality, frequently developing severe pulmonary edema and widespread inflammation, which can lead to acute respiratory distress syndrome or acute lung injury [30]. Research using a mouse model of H1N1/MRSA co-infection has demonstrated that the activation of the complement pathway contributes to increased severity of ALI and associated mortality. In this model, therapeutic strategies aimed at targeting complement activation, specifically through the use of cobra venom factor (CVF) to deplete C3 or employing anti-C5aR to inhibit C5a receptor signaling, thus effectively suppressed complement overactivation, reduced inflammation, and consequently decreased lung injury and mortality [39]. These findings indicate that complement plays a crucial role in the progression of bacterial and viral co-infections, suggesting that targeting the complement system may represent a promising clinical strategy for managing such infections.
Excessive activation of the complement system significantly exacerbates the progression of hematological disorders, vascular diseases, autoimmune conditions, and inflammatory diseases (Table 1) [32]. For instance, in patients with PNH, somatic mutations in the phosphatidylinositol glycan class A coding gene within hematopoietic stem cells lead to a deficiency of decay-accelerating factor (CD55) and CD59 on the surface of blood cells. This deficiency results in complement-mediated intravascular hemolysis [33]. In addition to blood cells, endothelial cells represent another cell type that is closely associated with plasma complement and frequently becomes a target during hyperactivated complement responses [34]. When organs from xenogeneic species such as pigs are transplanted into humans or primates, preexisting natural antibodies in the recipient trigger the classical pathway of complement activation. These natural antibodies specifically recognize the gal-(α1,3)-gal epitope present in the endothelial cells of the donor organ. Complement activation induces severe injury to endothelial cell, leading to a loss of their natural anticoagulant properties and resulting in systemic intravascular coagulation. This cascade culminates in hyperacute rejection of the transplanted organ within minutes to hours [35]. The development of inhibitors targeting abnormal complement activation or employing genetically engineered donor pigs is of paramount importance for advancing clinical medicine.
Therapeutic prospects based on complement activation or inhibition
While dysregulation of the complement cascade can lead to adverse effects, strategically harnessing the functional properties of the complement system may provide substantial therapeutic benefits. On one hand, drug development frequently leverages complement-binding proteins to selectively activate the complement pathway for the destruction of tumors or pathogens. Pedersen et al. designed a bispecific complement engager, which comprises a nanobody that recruits the complement-initiating protein C1q and a single-chain variable fragment derived from broadly neutralizing antibodies targeting the HIV-1 envelope protein. This design aims to facilitate complement deposition on the surface of HIV-1-infected cells, thereby promoting complement-mediated cytolysis [40]. On the other hand, to mitigate infection risks associated with systemic inhibition of complement in clinical applications, researchers have developed bispecific antibodies (bsAbs) that enable targeted suppression of complements by simultaneously binding local antigens and endogenous complement regulatory factors. Wang et al. constructed a novel class of bsAbs wherein one Fab arm binds to a tissue-specific target while the other Fab arm interacts with endogenous human complement inhibitors. These bsAbs are capable of recruiting endogenous regulatory factors such as CFH or C4b-binding protein (C4BP) to the vicinity of specific cell surface antigens, thus achieving localized inhibition of complement. This approach represents an innovative strategy for targeted treatment of diseases mediated by complements [41].
Complement-mediated immune defence against pathogens
As a critical component of the frontline defense system, the complement system plays a crucial role in opsonization, phagocytosis, and the destruction of pathogens [42]. The activation of complement generates three major types of effectors: (1) anaphylatoxins (C3a and C5a), which are potent pro-inflammatory molecules that recruit and activate leukocytes through their interaction with specific G-protein-coupled receptors, namely the C3a receptor (C3aR) and the C5a receptor (C5aR); (2) opsonins (C3b, iC3b, and C3d), which covalently attach to target cells, serve to mark these cells for clearance while also facilitating the removal of immune complexes and apoptotic cells; and (3) MAC, which directly lyses targeted (opsonized) pathogens or damaged host cells. These effectors enable the complement system to play a pivotal role in host defense against bacterial infections, immune complex clearance, and the removal of apoptotic cells [38]. While these three effectors can function independently to defend against pathogen invasion, they also interact synergistically to form a comprehensive network for complement-mediated defense. Additionally, the complement system serves as a critical bridge connecting innate and adaptive immunity. On one hand, complement activation products (e.g. C3d) covalently bind to pathogen antigens, resulting in the formation of antigen-antibody-complement complexes [43]. These complexes can be recognized by complement receptors 2 (e.g. CR2/CD21) on B cells, significantly enhancing the capture and presentation of antigen by B cells while also promoting their activation, proliferation, and antibody production. This process ultimately boosts the humoral immune response [44]. On the other hand, complement components (e.g. C3a, C5a) also play a role in modulating T cell function [45].
Cytolytic activity of the membrane attack complex
The MAC is an asymmetric, flexible barrel-shaped structure assembled from five distinct complement components (C5b, C6, C7, C8, and multiple copies of C9) [46]. The mechanism underlying MAC-mediated cytolysis has been preliminarily elucidated. Upon pathogen invasion, host recognition triggers the activation of the CP, AP, or lectin pathway (LP), all of which lead to the deposition of C3b on cellular surfaces. C3b combines with C3 convertases derived from all three pathways to form C5 convertases that cleave C5 into two fragments: the anaphylatoxin C5a and the membrane-binding fragment C5b. The stable association between C5b and C6 results in the formation of the complex known as C5b6, which subsequently binds to C7 to generate the intermediate complex referred to as C5b67. Within this assembly, subunit C7 initiates penetration into the lipid bilayer of the target cells. Following this initial interaction, the binding of C8 to the pre-formed C5b67 complex enables partial insertion into the membrane. This assembly recruits approximately 12–15 C9 molecules that polymerize within the lipid bilayer to create a stable transmembrane pore approximately 10 nm in diameter. The formation of this pore induces directional destabilization of membranes through ion gradient dysregulation and loss of mitochondrial membrane potential, ultimately leading to cellular lysis and pathogen elimination (Figure 1(A)) [47,48].
Figure 1.

Immune defense mechanisms of the complement system. (A) cytolysis mediated by the membrane attack complex (MAC). Sequential assembly of C5b-9 leads to pore formation on the pathogen surface, resulting in cell lysis. (B) opsonophagocytosis enhances pathogen clearance. Complement opsonins (e.g. C3b) facilitate pathogen recognition and phagocytosis by macrophages and neutrophils through their interaction with complement receptors (CRs) and fc receptors (FcRs). (C) induction of inflammation via complement signaling. C3a and C5a interact with their respective receptors (C3aR, C5aR) to activate inflammatory pathways, including the NLRP3 inflammasome, leading to cytokine production and enhanced immune responses. (D) connecting innate and adaptive immunity. Complement components regulate B cell activation through CR2 (CD21) and enhance antigen presentation and phagocytosis via dendritic cells (DCs). CRs on T cells promote chemotaxis and activation, thereby linking innate and adaptive immune response.
Complement activation and the assembly of the MAC can occur on various cell surfaces, including those of bacteria, parasites, enveloped viruses, and abnormal host cells [46]. Studies have shown that different types of microorganisms exhibit varying sensitivities to complement-induced lysis. Most enveloped viruses, such as orthomyxoviruses (e.g. influenza virus), paramyxoviruses (e.g. respiratory syncytial virus), and retroviruses (e.g. HIV), are highly susceptible to complement-mediated lysis [49]. Gram-negative bacteria are particularly vulnerable to the cytolytic effects of complement because the MAC targets the junction between their inner and outer membranes. This disruption compromises membrane integrity and leads to cytoplasmic leakage [2]. N. meningitidis, a Gram-negative bacterium, is highly sensitive to MAC-mediated killing, thus, individuals deficient in MAC components are particularly susceptible to severe meningococcal infections [50]. While many bacteria are susceptible to MAC attack, some possess natural resistance due to structural characteristics. For instance, Gram-positive bacteria are generally protected from MAC-mediated lysis owing to their thick cell wall which prevents penetration by the MAC into the cytoplasmic membrane. Certain encapsulated bacteria utilize their surface capsule structures to resist complement-mediated cytolysis. For instance, Actinobacillus pleuropneumoniae evades antibody-dependent bactericidal activity and complement-mediated killing through its capsule polysaccharides and lipopolysaccharides, which specifically block antibody binding [51]. In contrast, S. pneumoniae strains that produce capsules enhance their invasive infection capacity by reducing the deposition of complement C3b on bacterial surfaces [52].
Opsonophagocytosis-differential recognition of Gut commensals and pathogens
Opsonophagocytosis refers to the process by which antibodies and complement components, along with other proteins, coat pathogenic antigens. This coating facilitates their recognition by Fc receptors (for antibodies) or complement receptors (CRs) (for complement components) on phagocytes. Such recognition subsequently triggers phagocytosis mediated by CRs and leads to pathogen destruction [2]. The C3 convertases generated through all three pathways of complement activation produce C3b fragments, thereby initiating the complement cascade. Consequently, the complement system serves as a crucial effector for “tagging” and eliminating foreign substances. During the activation of the complement system, key opsonins such as C3b, C4b, and iC3b deposit onto the surface of bacteria or other particulate matter. By binding to specific CRs (CR1–4 or CRIg) on phagocytes, these opsonins significantly enhance the efficiency of phagocytosis (Figure 1(B)) [47].
CR1 (CD35) is a key participant in the interactions involving surface-bound iC3b. It not only interacts with C3b and C4b to facilitate neutrophil-mediated phagocytosis but also aids in the subsequent cleavage of its ligands into C3dg via CFI induction. Both CR3 (CD11b-CD18) and CR4 (CD11c-CD18) are capable of binding to iC3b fragments, thereby contributing to the process of phagocytosis. Furthermore, CR3 plays a role in regulating cytokine responses, leukocyte trafficking, and synapse formation [24,53].
CRIg serves as a macrophage receptor for both C3b and iC3b, playing a pivotal role in the phagocytic elimination of pathogens opsonized by C3 [54]. It significantly contributes to the intravascular clearance of blood-borne parasites [55]. As a pattern recognition receptor for lipoteichoic acid, CRIg enables hepatic macrophages to efficiently capture and eliminate Gram-positive bacteria in the liver [56]. Additionally, CRIg facilitates autophagosome formation, which allows for the clearance of Listeria monocytogenes that have escaped from phagosomes following C3 opsonization [57]. Hajishengallis et al. and Hasegawa et al. demonstrated that in a mouse model of Clostridioides difficile-induced intestinal injury, upregulated IL-22 expression effectively stimulated C3 production in both the liver and intestine. This increased expression of C3 enhanced opsonization and promoted neutrophil-mediated bacterial phagocytosis, thereby safeguarding the host against secondary systemic infections resulting from intestinal barrier damage [4,58].
Wu et al. discovered that the intestinal complement system effectively eliminates pathogenic bacteria through opsonophagocytosis while sparing intestinal commensal bacteria [10]. This selective clearance mechanism is manifested in three distinct ways: molecularly, the specific structure of the intestine lacks lytic components (C5-C9), thereby protecting commensal bacteria from lysis; spatially, phagocytes are absent from the intestinal lumen under steady-state conditions, which prevents accidental damage to commensals; and functionally, the opsonophagocytic pathway is activated solely during infection – pathogen invasion triggers C3 deposition on the pathogen surface, forming an “eat-me” signal that recruits neutrophils to the intestinal lumen for pathogens clearance via C3-mediated phagocytosis. Importantly, a bidirectional regulatory relationship exists between microbiota formation and this mechanism: the composition of the microbiota determines baseline C3 levels, which in turn influences the host’s capacity for anti-infection responses. Consequently, by regulating C3 levels, the microbiota serves as a “rheostat” that can enhance or reduce the host’s ability to combat infections. This finding paves the way for innovative therapeutic strategies aimed at targeting microbiota in efforts to address infectious diseases.
Both circulating and intracellular complement can activate inflammation
Anaphylatoxins are small peptide fragments derived from the cleavage of C3 and C5 in the complement system, specifically including C3a and C5a [2]. These proteins, approximately 9 kDa in size, exhibit structural similarities and play a crucial role in promoting inflammation while serving as chemotactic agents for certain types of leukocytes. The C-terminal loop regions of anaphylatoxins C3a and C5a adopt a “Hook” conformation, which anchors them to the positively charged binding pocket of their respective receptors, thereby forming the primary interaction interface [59]. The binding of anaphylatoxins to their corresponding receptors induces conformational changes in the intracellular domains, leading to G-protein coupling and downstream signal transduction. This cascade triggers the secretion of soluble pro-inflammatory mediators such as IL-6 and TNF-α [24,47]. These cytokines enhance local vascular permeability, facilitating leukocyte migration toward sites of infection while also increasing smooth muscle motility to promote fluid transport to areas of tissue damage [60]. Additionally, both C3a and C5a interact with their respective receptors on mast cells and basophils. This interaction results in cellular degranulation along with enhanced phagocytosis of invading pathogens, subsequently releasing a second wave of inflammatory mediators such as histamine and prostaglandins [53]. These mediators further accelerate lymphocyte trafficking to nearby lymph nodes where they become activated by pathogens. This localized inflammatory response is further reinforced by systemic effects such as fever that serve to reduce microbial viability [2,61].
In human monocytes, C3a-induced activation of surface C3aR triggers the release of ATP into the extracellular space. This mechanism regulates P2×7activation and synergizes with Toll-like receptor signaling to activate the NLRP3 inflammasome (Figure 1(C)). Consequently, this process leads to the secretion of IL-1β by monocytes, which in turn promotes IL-17 production in human CD4+ T cells [62]. Riley and colleagues found that C3-deficient mice infected with Rickettsia australis exhibited reduced interferon-gamma production, reduced IgG secretion, and impaired spleen hyperplasia. The observed correlation between secondary immune dysfunction and complement deficiency suggests that pro-inflammatory signaling components of the complement system, rather than the membrane attack complex or opsonophagocytosis, contribute to the immune response against this pathogen [63]. Mustapha et al. used a Rickettsia-infected monocyte model to elucidate the role of complement activation and the anaphylatoxin/anaphylatoxin receptor axis in regulating responses to infection. Their study revealed that anaphylatoxins activate macrophages, thereby limiting Rickettsia infection by restricting phagosome escape. Activated macrophages accumulate phosphorylated ERK1/2 proteins and enhance the transcription of monocyte activation markers and pro-inflammatory cytokines, thereby controlling intracellular Rickettsia proliferation [61]. In patients with α-1 antitrypsin deficiency, elevated levels of the complement activation product C3d in circulation and the respiratory tract induce NLRP3 and Pro IL-1β expression in monocytes through CR3 signaling. Additionally, C3d triggers caspase-1 activation and IL-1β secretion by inducing endoplasmic reticulum stress and calcium ion flux [64]. In patients with gouty arthritis, monosodium urate crystals present in the joints induce complement activation, consequently, C5a generated during this cascade promotes IL-1β production via reactive oxygen species, leading to increased neutrophil recruitment and subsequent activation of the NLRP3 inflammasome. Thus, the C5a-C5aR1 signaling axis has been identified as a key determinant of IL-1β-mediated inflammatory cell recruitment (Figure 1(C)) [65].
In recent years, the understanding of the complement system has evolved from being perceived solely as a blood-based antimicrobial system to recognizing it as a global regulator of immune and tissue homeostasis [4]. Recent studies have demonstrated that the complement system encompasses not only extracellular complement components secreted by the liver and macrophages, which exert their activity in the vasculature and extracellular environment but also comprises intracellular complement molecules that actively function within cells. These intracellular components share identical encoding genes with their extracellular counterparts found in the liver and bloodstream [11]. The intracellular complement system (ICS) consists of a unique high-order protein complex distinct from its extracellular counterpart, referred to as the “complosome” [4,11]. Emerging evidence suggests that certain cell types, particularly T cells, have the capacity to synthesize complement components (e.g. C3) intracellularly. This intracellular reservoir of C3 likely originates from alternatively spliced mRNA isoforms present in the cytosol, thereby enabling these components to exert immunomodulatory functions at non-canonical sites [66]. Intracellular complement is widely present in both immune and nonimmune cells, with the complosome primarily localized in various cellular compartments including the cytoplasm, lysosomes, endoplasmic reticulum, outer mitochondrial membrane, and nucleus. It can interact both internally among its constituents and externally with intracellular danger sensors and effector systems [4,11]. Observations of intracellular cleavage of C3 and C5 in various immune cells, including lymphocytes [67], monocytes, and neutrophils, suggest that intracellular complement may play a role in signal transduction (Figure 1(C)) [68]. For instance, bacteria such as Salmonella Typhimurium can be detected in the cytoplasm through a C3-dependent mechanism after being opsonized by C3 fragments extracellularly. This detection triggers mitochondrial antiviral signaling protein, which subsequently activates multiple transcription factors-including NF-κB, AP-1, and interferon regulatory factors (IRF-3 and IRF-5) to induce pro-inflammatory cytokines expression [4].
Therefore, targeting the interactions between C3a-C3aR and C5a-C5aR to modulate inflammatory responses not only holds significant therapeutic potential for related diseases but also represents a promising avenue for scientific research. Moreover, this strategy has emerged as a focal point in the development of novel treatments for inflammation-related disorders.
The role of complement in bridging innate and adaptive immunities
The complement system plays a pivotal role in initiating the inflammatory response upon pathogen invasion. In addition to this primary function, it aids in the maturation of antigen-presenting cells (APCs), facilitates the activation of B and T cells within lymph nodes, and induces a regulated effector T cell response in tissues [11]. Additionally, the complement system contributes to tagging “foreign” pathogens for recognition by B cells, thereby enhancing antibody production and contributing to the establishment of long-term immune memory (Figure 1(D)) [13,44].
Macrophages and APCs serve as crucial links between innate and adaptive immunity [11]. Dendritic cells (DCs), follicular dendritic cells (FDCs), and macrophages express a variety of known CRs. MBL, C1q, C3b, and C4b bind to pathogen-associated molecular patterns and interact with receptors on APCs during the process of antigens recognition, thereby transmitting signals that enhance antigen uptake [2]. Intracellularly activated C3 fragments in APCs associate with engulfed apoptotic cells, modulating the intracellular trafficking of their cargo into lysosomes and delaying phagosome maturation within DCs. This mechanism ultimately enhances antigen presentation [60]. These findings suggest that complement components binding to APCs not only enhance their phagocytic capacity but also regulate cytokine secretion.
The complement system regulates B cell immunity through various CRs and regulatory factors expressed on the surfaces of both B and T cells (Figure 2(D)). When an antigen (Ag) is opsonized with the complement fragment C3d, Ag-C3d complexes are formed, enabling CR2 (CD21) on the surface of B cells to associate with the signaling protein CD19 and the tetraspanin protein CD81, thereby creating a B cell co-receptor complex. This complex recognizes C3d within the Ag-C3d complex via CR2 while simultaneously allowing the B cell receptor (BCR) to identify the antigenic component. The co-ligation of these receptors significantly amplifies BCR signaling and lowers the activation threshold for B cells, ultimately initiating their activation and proliferation [43,69]. Following this activation, B cells migrate to lymphoid follicles where they form germinal centers (GCs). Within these GCs, FDCs capture and retain Ag-C3d complexes over extended periods through their surface receptors CR1 (CD35) and CR2 (CD21), presenting these complexes to B cells located within the GC. This process is critical for sustaining GC reactions; deficiencies in CR2/CR1 lead to increased apoptosis among GC B cells and impaired antibody responses [70]. Furthermore, it has been discovered that complement C3 and its receptors participate in capturing and transporting lymph-borne Ag to FDCs, revealing a key mechanism by which complement enhances adaptive immunity. Leveraging this mechanism, employing C3d as a molecular adjuvant to enhance vaccine immunogenicity has emerged as an effective strategy. For example, Qi et al. designed and expressed a C3d-fused porcine circovirus type 2d virus-like particle (PCV2d VLP). This vaccine induced an earlier and more robust immune response in both mice and pigs while effectively reducing PCV2d viral load post-challenge; it also provided significant protection [71], thus demonstrating the practical utility of utilizing C3d as an adjuvant strategy.
Figure 2.

Microbial strategies for evasion of complement and mechanisms of complement-mediated immune defense. This schematic illustrates the intricate interplay between microbial strategies for evading complement-mediated immune responses and the host’s complement system. On the left, four major microbial strategies are shown: (A) the expression of enzymatically active proteins that degrade complement components (e.g. LIC13322 from Leptospira, which degrades C9 to prevent MAC assembly), (B) the expression of complement-interacting proteins that inhibit complement activation (e.g. SIC from streptococcus pneumoniae blocking C5b-9/MAC formation), (C) the secretion of proteins that mimic complement ligands to competitively bind host complement receptors (e.g. Plasmodium proteins Rh4 and PvEBP binding to complement receptor 1 (CR1)), and (D) the recruitment of host negative regulators of complement to suppress activation (e.g. bordetella pertussis Vag8 interacting with C1 inhibitor (C1INH) to inhibit both classical (CP) and lectin (LP) pathways). On the right, the activation cascades of the canonical complement pathways are illustrated: classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). This depiction highlights key activation complexes (e.g. C3 and C5 convertases) and regulatory factors (e.g. soluble regulators like factor H (CFH), membrane inhibitors such as CD59, and membrane cofactor proteins like CD46 (MCP)). Complement activation leads to various effector functions, including opsonophagocytosis, inflammation, cytolysis via membrane attack complex (MAC) formation, and bridging innate and adaptive immunity. This figure underscores the evolutionary arms race between pathogens and host immunity through specific modulation of complement pathways.
The complement system also plays a crucial role in T-cell development, homeostasis, and immune responses (Figure 1(D)). Immature T cells are protected from natural antibody- and complement-mediated lysis due to the presence of additional sialic acid residues on their surface glycoproteins. In contrast, T cells that lack sialic acid are more susceptible to complement recognition and lysis, resulting in their elimination during development [2]. In resting CD4+ T cells, endogenously generated C3a, cleaved by cathepsin L, activates C3aR on lysosomes. This activation leads to low-level mTOR activity that supports T-cell homeostasis [4,72]. Studies involving C3-deficient mice have shown delayed viral clearance and increased pulmonary viral load during influenza virus infection. Additionally, bronchoalveolar lavage fluid obtained from these mice reveals a reduced population of CD4+ and CD8+ T cells, suggesting that C3 promotes antigen-specific immune responses by inducing T-cell activation and migration during influenza infection [73]. Similar findings were reported by O’Brien et al. in a study conducted on C3-knockout mice infected with highly pathogenic avian influenza virus (H5N1), where the absence of C3 was associated with delayed viral clearance, increased morbidity, significant weight loss, and exacerbated tissue damage [74].
The complement system serves as a critical interface between innate and adaptive immunity. However, research exploring the interplay between complement components and regulatory proteins in influencing APCs, T cells, and B cells remains in its early stages. The precise mechanisms underlying these interactions require further elucidation.
The complement system synergistically enhances anti-infective responses through multiple mechanisms
The complement system rarely operates through a single mechanism when combating pathogens; rather, it typically engages two or more synergistic cytotoxic pathways. For instance, the complement system employs multiple defense strategies to counter respiratory viral infections. It enhances host defense by promoting antibody-mediated, complement-dependent lysis of viral particles and infected cells, thereby aiding in virus neutralization and promoting T-cell activation. Nevertheless, it can also exacerbate disease severity and mortality due to the pro-inflammatory effects of complement components, such as the anaphylatoxins C3a and C5a, along with the formation of the MAC [68].
The different complement activation pathways work synergistically to enhance antiviral defense. Rattan et al. investigated the impact of different complement pathways on the control of H1N1 pdm09 infection. The virus demonstrated sensitivity to CP-mediated neutralization, as all C3-deficient mice succumbed to infection. In contrast, it exhibited resistance to AP- and LP-mediated neutralization, with only partial mortality observed in C4- or FB-deficient mice. Notably, when the virus was opsonized by specific antibodies, it became susceptible to AP-mediated neutralization. In this scenario, AP-loop activation further amplified CP-induced complement activation, thereby enhancing CP-mediated neutralization. Additionally, the complement activation process generated a substantial amount of C3a, which, upon binding to C3aR on immune cell surfaces, further activated these immune cells and reinforced the protective immune response. These findings confirm that the synergy between CP and AP is crucial for the effective prevention of H1N1 pdm09 virus infection [75].
Moreover, both circulating and intracellular complements collaborate synergistically to exert antimicrobial functions. In research investigating the role of C5 from different sources in candidemia, Desai et al. found that both Albumin-Cretg/C5fl/fl mice (which lack C5 in hepatocytes, leading to plasma C5 deficiency) and Lyz2-Cretg/C5fl/fl mice (with a knockout of C5 in myeloid cell lineages) exhibited increased mortality rates along with higher fungal burden in the kidneys and impaired renal function following Candida infection. These experimental results demonstrate that locally produced C5 plays a critical role in fungal defense within infected tissues alongside liver-derived C5 [76].
Microbial complement evasion strategies
Successful infection inherently implies the occurrence of immune evasion or subversion events. Given the continuous activity of the immune system, pathogens must penetrate the first line of defense upon encountering the host, migrate to their preferred ecological niche (or disseminate systemically), and complete replication. As an ancient immune mechanism, the complement system can be activated within minutes to hours of following initial contact with a pathogen. To counter this rapid activation, pathogens have evolved various strategies to evade or disrupt complement activation and effector functions, thereby enhancing their survival and/or virulence. Gram-positive bacteria possess robust cell walls that effectively shield them from MAC insertion [77], while some bacteria evade immune detection by taking refuge within host cells. These two strategies are widely utilized by microorganisms; however, in addition to these general tactics, microbes have developed more specific mechanisms for complement evasion to avoid destruction (Figure 2).
Pathogenic bacteria express enzymatically active proteins to degrade complement proteins: a direct assault
Proteases serve as a crucial weapon for bacteria to evade complement-mediated immunity. Numerous pathogens secrete proteases capable of cleaving and degrading complement factors at both local and systemic levels.
The ScpA protein from Streptococcus pyogenes (S. pyogenes) is a multi-domain subtilisin-like serine protease associated with the cell envelope [78]. On one hand, ScpA cleaves C3a, thereby impairing the activation, phagocytosis, and chemotaxis of human neutrophils. Simultaneously, it cleaves C3 into abnormally sized and functionally impaired fragments of C3a and C3b, which further reduces the phagocytosis activity and clearance of bacteria [79]. On the other hand, ScpA also cleaves the anaphylatoxin C5a into inactive fragments, disrupting the C5a-C5aR signaling axis. This disruption suppresses inflammation induced by complement activation and prevents neutrophil recruitment to the site of infection [78,80]. S. aureus secretes multiple serine protease-like proteins, among which SplB preferentially targets and cleaves the α-chain of both C3 and C4, leading to their degradation. Additionally, it further cleaves components of the terminal complement pathway, including C5, C6, C7, C8, and C9, thereby reducing neutrophil-mediated opsonophagocytosis via reduced availability of active C3b and limiting deposition of the C5b-9 on the bacterial surface [81]. The strategies employed by Gram-positive cocci such as Streptococcus and S. aureus for evading complement-mediated responses have been comprehensively reviewed by Laabei et al. [82] and Loh et al. [77].
Gram-negative bacteria can also evade the complement system by secreting enzymatically active proteins [83]. Freire et al. discovered that the extra-intestinal pathogenic E. coli (ExPEC) strain EC071 exhibits resistance to the bactericidal activity of normal human serum. This strain secretes a serine protease known as Sat, which cleaves multiple complement components, thereby inhibiting complement activity and facilitating ExPEC-induced bloodstream infections and sepsis [84]. Pathogenic Leptospira species secrete various proteases, including the metalloprotease LIC13322, which can directly interact with individual proteins of the C6-C9 complex. By preventing MAC formation and subsequent pathogen lysis, these proteases assist bacteria in evading complement-mediated killing (Figure 2(A)) [85].
P. aeruginosa employs the metalloprotease AprA to cleave C1s, C3, and C4, thus diminishing complement-mediated opsonophagocytosis and reducing C3b deposition through both lectin and classical pathways. AprA competitively cleaves C2, preventing its natural cleavage into C2a and C2b, this action inhibits the activation of both the CP and LP [86]. Furthermore, AprA impedes terminal complement complex formation by blocking the cleavage of C5 into C5a and C5b since C5b serves as a molecular scaffold during MAC assembly [87]. Additionally, P. aeruginosa secretes elastase PaE and alkaline protease PaAP that target complement components such as C1q and C3 respectively, thereby preventing the activation of the entire complement cascade [87,88].
Research conducted by Krzyżewska-Dudek et al. has demonstrated that the outer membrane protein PgtE of non-typhoidal Salmonella cleaves the complement component C3b into fragments similar to those produced by CFI, thereby inhibiting the formation of C3 convertase in the AP. In addition to its action on C3b, PgtE is also capable of cleaving components C4b and C5, as well as degrading CFB and CFH. This activity significantly enhances the survival rate of Salmonella following their exit from phagocytic cells [29].
Pathogens express complement-interacting proteins to inhibit complement function–muddying the waters
In addition to directly cleaving complement proteins, pathogens can express and secrete certain proteins that bind to complement components, thereby disrupting complement function at various stages. These proteins are typically classified as adhesins, outer membrane proteins, and outer membrane lipoproteins.
Streptococcus is a major pathogen capable of causing life-threatening invasive diseases [89] and possesses multiple strategies for evading complement-mediated responses [82]. The pneumococcal surface proteins GAPDH and endopeptidase O serve as ligands for C1q [14], facilitating the evasion of complement-mediated bacterial lysis by binding to human complement factor C1q [19]. The M1 and M57 strains of S. pyogenes secrete a complement inhibitory protein known as SIC, which interacts with the C5b-9 ring structure. This interaction prevents the induction of lysis in sensitized sheep and guinea pig erythrocytes [90], thereby contributing to immune resistance [91]. Furthermore, Streptococcus can interfere with the assembly of the MAC by utilizing the glycolytic enzyme phosphoglycerate kinase (PGK) to bind MAC components C5 and C7 instead of C9 (Figure 2(B)) [92].
Schindler et al. discovered that Yersinia enterocolitica adhesin A (Yersinia adhesive, YadA) recruits C3b and iC3b to the bacterial surface. The binding of C3b subsequently facilitates the further recruitment of factor H, which promotes the factor I-mediated conversion of C3b into iC3b. Meanwhile, the presence of iC3b on the bacterial surface inhibits the formation of the terminal complement complex (TCC, C5b-9), thereby protecting Yersinia from complement-mediated lysis [93]. In S. aureus, the extracellular adherence protein (Eap) binds to C4b, inhibiting the binding of C2 and its fragment C2b, thereby blocking the assembly of the C3 convertase (C4b2a). Additionally, Eap suppresses activation through both AP and LP [94].
Various outer membrane proteins (Omp) in Gram-negative bacteria play a critical role in evading complement-mediated immunity. For instance, in E. coli K1 strains, OmpA interacts with C4BP [95], which subsequently facilitates degradation processes for both C3b and C4b [96], this action effectively hinders the proper formation of the MAC. Furthermore, mutations in OmpC enhance bacterial survival in serum by inhibiting classical complement pathway activation, specifically by blocking C1q and anti-OmpC antibody-dependent activation [97]. Collectively, these mechanisms contribute significantly to bacteria’s ability to resist complement-mediated killing while persisting within their host environment. The complement resistance protein TraT is an outer membrane lipoprotein that is exposed on the surface of bacterial cells. In E. coli K12 and Salmonella Typhimurium, TraT reduces excessive deposition of C3b on bacterial surfaces, thereby enhancing bacterial survival in serum [98]. Furthermore, purified TraT protein may inhibit complement-mediated lysis of sensitized erythrocytes by preventing the formation of the C5b6 complex or altering the structure of the MAC, which further improves bacterial survival in serum [99]. In Edwardsiella tarda, TraT binds to and recruits CFH, inhibiting activation of the AP. Moreover, TraT interacts with host CD46 in a manner dependent on its complement control protein domain, thereby promoting bacterial infection and tissue dissemination [100]. Similarly, the outer membrane lipoprotein increased serum survival factor (Iss) contributes to virulence and serum resistance in avian pathogenic E. coli [101,102], although its precise mechanism of action remains unreported.
Pathogens secrete complement-like proteins to compete for receptor binding–seizing control
CRs are expressed on the surface of cells in both the innate and adaptive immune systems. They mediate host recognition of pathogens and danger-associated molecules by establishing a physical link between fluid-phase complement factors and cellular immunity [53]. Additionally, CRs regulate complement activation on host cells, facilitate the clearance of immune complexes, and control the phagocytosis of opsonized particles. Given the long-standing evolutionary conflict between immune cells and pathogens, it is plausible that pathogenic infection factors have evolved mechanisms to exploit CRs for entry into human host cells. Evidence suggests that some pathogens deliberately activate the complement system to aid in disease progression, a phenomenon often referred to as “hitchhiking” or “complement hijacking.” This strategy is particularly employed by intracellular pathogens such as Mycobacterium tuberculosis and specific viruses, which recruit complement proteins to their membranes or surfaces as a means of camouflage, thereby facilitating their entry into host cells [28,79].
Plasmodium mediates erythrocyte invasion and infection by binding to CR1 on the erythrocyte surface through reticulocyte-binding protein homolog 4 and Plasmodium vivax erythrocyte binding protein, specifically interacting with the first subdomain of CR1 (Figure 2(C)) [103]. Epstein-Barr virus utilizes viral glycoprotein gp350 and CR2 (CD21) as a common pathway for entering T cells and B cells [104]. Neisseria gonorrhoeae (N. gonorrhoeae) invades cervical epithelial cells via CR3, resulting in cervicitis. The interaction between pilin glycans on N. gonorrhoeae and the I-domain of CR3 triggers signaling pathways in primary human cervical epithelial (Pex) cells. This process leads to CR3 activation, internalization of N. gonorrhoeae into Pex cells, upregulation of CR3 on the surface of Pex cells, and intracellular replication of N. gonorrhoeae [105,106]. Day et al. discovered that CR3 mediates the transcytosis of HIV-1 across the intact cervical epithelial cell barrier, suggesting that the CR3/Pex axis may constitute an effective route for HIV-1 transmission in women [107]. However, the specific HIV proteins involved in this process remain unidentified.
Pathogens recruit complement negative regulators to inhibit complement activation–using the enemy’s weapon
To mitigate the destructive potential of the complement system, the body has evolved strict regulatory proteins known as complement-negative regulators, which are essential for maintaining self-protection [1,108]. These include C1INH, CFI and CFH, C4BP, vitronectin (Vn), and clusterin [109]. Their primary function is to limit complement-mediated damage to microbes while preventing excessive activation that could harm host tissues [2,32,38]. These regulators act at different stages of the complement cascade. Meanwhile, pathogens evade immune responses by recruiting or binding complement regulatory proteins such as FHBP and C4BP [29,110].
C1INH is a serine protease inhibitor that suppresses serine proteases C1r in the classical pathway and MASP-2 in the lectin pathway. This action prevents further activation of C4 and C2, thereby inhibiting the formation of C3 convertase [2,111]. The Bordetella pertussis autotransporter protein Vag8 recruits C1INH, which irreversibly inactivates both esterase enzymes, C1r and C1s, involved in the CP as well as MASP-1/-2 proteases in the MBL/Ficolin complex associated with the lLP [112,113], thereby effectively inhibiting the complement cascade (Figure 2(D)).
The impact of CFH on the complement system is primarily attributed to its regulatory role concerning the key component C3b during the activation of the AP [114]. FHBP, a surface-exposed protein found in N. meningitidis, engages in a high-affinity interaction with CFH on the bacterial surface. This interaction enables N. meningitidis to modulate host complement activation, inhibit opsonization, and enhance its survival in human serum, leading to meningitis and sepsis [115,116]. N. gonorrhoeae surface protein A (NspA) binds to CFH domains 6 and 7, thereby increasing resistance against serum-mediated attacks [117]. Mycoplasma pneumoniae utilizes heat-unstable elongation factor Tu (EF-Tu) to bind CFH, which results in reduced deposition of C3 on the pathogen surface and facilitates evasion from complement activation processes [118]. Meri and colleagues discovered that various pathogens, including Haemophilus influenzae, Bordetella pertussis, P. aeruginosa, S. pneumoniae, Candida albicans, Borrelia burgdorferi, and Treponema species can interact with domain 20 of CFH through their respective proteins. This interaction forms a ternary complex comprising microbial protein-C3b-CFH that more effectively inhibits complement activation [119]. Several proteins have been shown to facilitate infection via this strategy; these include OspE from Borrelia burgdorferi [120], FhbA from Borrelia hermsii [121], and Tuf from P. aeruginosa [122], can facilitate infection through this strategy.
C4BP is a potent soluble inhibitor of both the classical and lectin pathways of the complement system [123]. The outer membrane lipoprotein Nlpl from neonatal meningitis E. coli (NMEC) facilitates the recruitment of the complement regulator C4BP to the surface of NMEC, enabling it to evade serum bactericidal activity [124]. Meningococcal porin (Por) A binds C4BP, effectively escaping activation by the classical pathway [125]. Pneumococcal PspC4.4 recruits C4BP to the bacterial surface, leading to the decay of both CP and LP C3 convertases as well as the proteolytic cleavage of C4b. This process subsequently inhibits the formation of the MAC while also reducing bacterial phagocytosis due to decreased deposition of C3b and generation of C5a [126]. The virulence factor M protein from Group A Streptococcus is responsible for recruiting human C4BP to its surface, thus evading destruction by the immune system [127].
Vn is a multi-domain glycoprotein found in blood and extracellular matrix across various tissues. It plays a key role in regulating MAC formation and mediating cell adhesion [109]. Bacterial receptors that bind Vn can prevent lysis induced by MAC formation [128]. For example, Rickettsial Adr1 and Adr2 bind both the complement regulator CFH and terminal pathway inhibitor Vn simultaneously [129–131]. The outer membrane protein OMP76 from Riemerella anatipestifer enhances complement evasion and virulence through its binding with duck complement factor Vn [132]. Similarly, dengue virus NS1 interacts with Vn as well as terminal complement proteins to inhibit MAC formation [133].
Cooperative role of bacterial proteins in complement evasion
Due to the complexity of the complement system and the diversity of its activation pathways, pathogens often use multiple resistance factors to evade complement-mediated attacks. This strategy is widespread among microorganisms. Studies have shown that numerous pathogens, including Gram-positive bacteria such as S. aureus [77], P. aeruginosa [87], Streptococcus spp [82,89], as well as Gram-negative bacteria such as Yersinia spp., Neisseria spp [22,134], Burkholderia spp [135], E. coli, Salmonella spp [29,83], spirochetes [85], and parasites [28] have evolved various mechanisms to evade complement-mediated attacks. These strategies have been extensively reviewed by other researchers. With further scientific advancements, it is anticipated that additional molecules involved in complement evasion molecules will be identified, leading to a clearer understanding of their underlying mechanisms.
Current therapeutic strategies targeting pathogen-complement interactions: progress and limitations
At present, the majority of therapeutic drugs aimed at modulating the complement system are peptides, small-molecule inhibitors, and monoclonal antibodies. More than 20 therapeutic agents targeting different components and effector pathways of the complement cascade are currently under clinical development, each with distinct indications. Mastellos et al. have provided a comprehensive review on this topic [136]. Nevertheless, certain challenges persist in clinical practice. For instance, in models of pneumococcal meningitis in mice, adjunctive treatment with C5 antibodies (such as eculizumab) has been shown to prevent brain injury and reduce mortality rates. However, this approach also inhibits the formation of the MAC, which may result in decreased clearance of meningococcal and an increased susceptibility to meningococcal disease [134].
In recent years, the repertoire of evasive pathogens and their specific complement targets has substantially increased. Researchers have employed diverse methodologies to demonstrate that pathogen binding to complement components or regulatory factors facilitates complement evasion. Consequently, key virulence factors participating in this process are now regarded as potential vaccine targets. These targets operate by enhancing pathogen susceptibility to complement-mediated defenses, thereby offering novel strategies for infection prevention and control [4]. Microbial complement inhibitors offer dual advantages in vaccine development. First, immune responses directed against these inhibitors enable specific recognition of the microorganisms. Second, they neutralize the pathogenic effects induced by critical virulence factors associated with these pathogens. Bacterial complement inhibitors typically operate through mechanisms such as binding soluble inhibitors (e.g. CFH or C4BP), blocking C3 or C5 activation, or enzymatically cleaving key complement components [137].
FHBP of N. meningitidis serves as a key antigen for the development of vaccines targeting N. meningitidis serogroup B (MenB) [138]. The currently licensed MenB vaccine (4CMenB, Bexsero) consists of outer membrane vesicles and three recombinant proteins, one of which is FHBP [139]. This vaccine has demonstrated robust protection against MenB infections in infants and young children in the United Kingdom [140]. This successful case offers promising prospects for vaccine development strategies based on microbial complement-binding proteins, an approach that is gaining increasing research interest. For example, Lewis et al. found that NspA binds to CFH, thereby enhancing N. meningitidis resistance to complement-mediated killing. As a result, NspA has emerged as a potential target for vaccines aimed at preventing meningococcal infections [141].
Current research primarily focuses on bacterial proteins that interact with soluble complement inhibitors. The essential criteria for bacterial proteins to serve as effective vaccine candidates include: (1) immunogenicity, (2) sequence conservation, (3) appropriate physicochemical properties, and (4) the ability to elicit an immune response capable of neutralizing critical bacterial virulence factors, particularly those associated with complement inhibitory activity [137]. Pathogens utilize redundant mechanisms to evade complement activation, and elucidating the functional mechanisms of different factors can aid in the selection of optimal candidate antigens for further investigation [137]. It is crucial to anticipate potential unintended consequences arising from complement deficiency or depletion when targeting the multi-protein cascade inherent in the complement system [142]. A comprehensive understanding of how pathogens circumvent complement defenses at immunological, molecular, and structural levels, as well as a thorough analysis of the diverse protein factors involved in complement evasion, is essential for advancing next-generation vaccines against these pathogens.
Conclusions and perspectives
Over the course of evolution, both the complement system and pathogens have developed diverse strategies for attack and resistance. As research progresses, a more profound understanding of complement mechanisms enables us to harness its potential to combat pathogens while simultaneously protecting the host from excessive complement activation. Additionally, tracking the evolution of pathogen strategies for evading complement responses and identifying potential molecules involved in this evasion can provide new targets for vaccine and drug development. Investigating the complex interplay between pathogens and the complement system relies on studying the direct and indirect interactions between proteins. Understanding these interactions is crucial for deciphering fundamental biological processes, elucidating the mechanisms that underlie various disease states, and developing urgently needed therapeutic interventions.
Acknowledgements
Siqi Lian (Conceptualization, Visualization, Writing – original draft, Writing – review & editing), Jiaqi Liu (Writing-original draft, Visualization, Writing – review & editing), Yi Yang (Visualization, Writing – review & editing), Guoqiang Zhu (Funding acquisition, Supervision, Writing – review & editing), and Pengpeng Xia (Conceptualization, Funding acquisition, Supervision, Writing – review & editing).
Funding Statement
This work was supported by the National Key Research and Development Program of China (2021YFD1800404), Grant No. 32072820, 31702242, 32402891 from the Chinese National Natural Science Foundation, and High Talent Supporting Program of Yangzhou University, and Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX23_3597), and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and Yangzhou Modern Agriculture Project (YZ2023040), and Yangzhou International Science and Technology Cooperation Project (YZ2023261); Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX23_3597]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
References
- [1].Nesargikar P, Spiller B, Chavez R.. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol. 2012;2(2):103–20. doi: 10.1556/EuJMI.2.2012.2.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [2].Punt J, Stranford SA, Jones PP, et al. Kuby Immunology.8th ed.New York: W. H. Freeman and Company; 2019. [Google Scholar]
- [3].Pouw RB, Ricklin D. Tipping the balance: intricate roles of the complement system in disease and therapy. Semin immunopathol. 2021;43(6):757–771. doi: 10.1007/s00281-021-00892-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [4].Hajishengallis G, Reis ES, Mastellos DC, et al. Novel mechanisms and functions of complement. Nat Immunol. 2017;18(12):1288–1298. doi: 10.1038/ni.3858 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5].Carpenter S, O’Neill LAJ. From periphery to center stage: 50 years of advancements in innate immunity. Cell. 2024;187(9):2030–2051. doi: 10.1016/j.cell.2024.03.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [6].de Bont C, Boelens W, Pruijn G. Netosis, complement, and coagulation: a triangular relationship. Cellular Mol Immunol. 2019;16(1):19–27. doi: 10.1038/s41423-018-0024-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [7].Bjanes E, Nizet V. More than a pore: nonlytic antimicrobial functions of complement and bacterial strategies for evasion. Microbiol Mol Biol Rev. 2021;85(1):85. doi: 10.1128/mmbr.00177-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8].Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16(11):601–617. doi: 10.1038/s41582-020-0400-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9].Hu S, Ottemann KM. Helicobacter pylori initiates successful gastric colonization by utilizing L-lactate to promote complement resistance. Nat Commun. 2023;14(1):14. doi: 10.1038/s41467-023-37160-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [10].Wu M, Zheng W, Song X, et al. Gut complement induced by the microbiota combats pathogens and spares commensals. Cell. 2024;187(4):897–913.e18. doi: 10.1016/j.cell.2023.12.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [11].Freeley S, Kemper C, Le Friec G. The “ins and outs” of complement‐driven immune responses. Immunol Rev. 2016;274(1):16–32. doi: 10.1111/imr.12472 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [12].Bohlson SS, Tenner AJ. Complement in the brain: contributions to neuroprotection, neuronal plasticity, and neuroinflammation. Annu Rev Immunol. 2023;41(1):431–452. doi: 10.1146/annurev-immunol-101921-035639 [DOI] [PubMed] [Google Scholar]
- [13].Heesterbeek Dani AC, Angelier M, Harrison R, et al. Complement and bacterial infections: from molecular mechanisms to therapeutic applications. J Innate Immun. 2018;10(5–6):455–464. doi: 10.1159/000491439 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [14].Terrasse R, Tacnet-Delorme P, Moriscot C, et al. Human and pneumococcal cell surface glyceraldehyde-3-phosphate dehydrogenase (GAPDH) proteins are both ligands of human C1q protein. J Biol Chem. 2012;287(51):42620–42633. doi: 10.1074/jbc.M112.423731 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [15].Conigliaro P, Triggianese P, Ballanti E, et al. Complement, infection, and autoimmunity. Curr Opin rheumatol. 2019;31(5):532–541. doi: 10.1097/bor.0000000000000633 [DOI] [PubMed] [Google Scholar]
- [16].Carroll MV, Sim RB. Complement in health and disease. Adv Drug Deliv Rev. 2011;63(12):965–975. doi: 10.1016/j.addr.2011.06.005 [DOI] [PubMed] [Google Scholar]
- [17].Wang SSY, Tang H, Loe MWC, et al. Complements and their role in systemic disorders. Cureus. 2024. doi: 10.7759/cureus.52991 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [18].Shih AR, Murali MR. Laboratory tests for disorders of complement and complement regulatory proteins. Am J Hematol. 2015;90(12):1180–1186. doi: 10.1002/ajh.24209 [DOI] [PubMed] [Google Scholar]
- [19].Honda-Ogawa M, Sumitomo T, Mori Y, et al. Streptococcus pyogenes endopeptidase O contributes to evasion from complement-mediated bacteriolysis via binding to human complement factor C1q. J Biol Chem. 2017;292(10):4244–4254. doi: 10.1074/jbc.M116.749275 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [20].Skattum L, van Deuren M, van der Poll T, et al. Complement deficiency states and associated infections. Mol Immunol. 2011;48(14):1643–1655. doi: 10.1016/j.molimm.2011.05.001 [DOI] [PubMed] [Google Scholar]
- [21].Willems E, Alkema W, Keizer-Garritsen J, et al. Biosynthetic homeostasis and resilience of the complement system in health and infectious disease. EBioMedicine. 2019;45:303–313. doi: 10.1016/j.ebiom.2019.06.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [22].Lewis LA, Ram S. Complement interactions with the pathogenic neisseriae: clinical features, deficiency states, and evasion mechanisms. FEBS Lett. 2020;594(16):2670–2694. doi: 10.1002/1873-3468.13760 [DOI] [PubMed] [Google Scholar]
- [23].Langereis JD, van der Molen RG, de Kat Angelino C, et al. Complement factor D haplodeficiency is associated with a reduced complement activation speed and diminished bacterial killing. Clin Transl Immunol. 2021;10(4):10. doi: 10.1002/cti2.1256 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [24].Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–797. doi: 10.1038/ni.1923 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [25].Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol. 2021;17(8):543–553. doi: 10.1038/s41581-021-00424-4 [DOI] [PubMed] [Google Scholar]
- [26].van den Heuvel L, Riesbeck K, El Tahir O, et al. Genetic predisposition to infection in a case of atypical hemolytic uremic syndrome. J Hum Genet. 2017;63(1):93–96. doi: 10.1038/s10038-017-0356-0 [DOI] [PubMed] [Google Scholar]
- [27].Vasilev VV, Radanova M, Lazarov VJ, et al. Autoantibodies against C3b—functional consequences and disease relevance. Front Immunol. 2019;10:10. doi: 10.3389/fimmu.2019.00064 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [28].Shao S, Sun X, Chen Y, et al. Complement evasion: an effective strategy that parasites utilize to survive in the host. Front microbiol. 2019;10:10. doi: 10.3389/fmicb.2019.00532 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [29].Krzyżewska-Dudek E, Kotimaa J, Kapczyńska K, et al. Lipopolysaccharides and outer membrane proteins as main structures involved in complement evasion strategies of non-typhoidal Salmonella strains. Mol Immunol. 2022;150:67–77. doi: 10.1016/j.molimm.2022.08.009 [DOI] [PubMed] [Google Scholar]
- [30].Jia L, Zhao J, Yang C, et al. Severe pneumonia caused by coinfection with influenza virus followed by methicillin-resistant Staphylococcus aureus induces higher mortality in mice. Front Immunol. 2019;9:9. doi: 10.3389/fimmu.2018.03189 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [31].Yu J, Yuan X, Chen H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020;136(18):2080–2089. doi: 10.1182/blood.2020008248 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [32].Kim DD, Song W-C. Membrane complement regulatory proteins. Clin Immunol. 2006;118(2–3):127–136. doi: 10.1016/j.clim.2005.10.014 [DOI] [PubMed] [Google Scholar]
- [33].Risitano AM, Frieri C, Urciuoli E, et al. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: from a pathogenic mechanism to a therapeutic target. Immunol Rev. 2022;313(1):262–278. doi: 10.1111/imr.13137 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [34].Noris M, Galbusera M. The complement alternative pathway and hemostasis. Immunol Rev. 2022;313(1):139–161. doi: 10.1111/imr.13150 [DOI] [PubMed] [Google Scholar]
- [35].Zhong R. Gal knockout and beyond. Am J transplantation. 2007;7(1):5–11. doi: 10.1111/j.1600-6143.2006.01615.x [DOI] [PubMed] [Google Scholar]
- [36].Dahmani M, Cook JH, Zhu JC, et al. Contribution of classical complement activation and IgM to the control of Rickettsia infection. Mol microbiol. 2021;116(6):1476–1488. doi: 10.1111/mmi.14839 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [37].González-Espinoza G, Barquero-Calvo E, Lizano-González E, et al. Depletion of complement enhances the clearance of Brucella abortus in mice. Infect Immun. 2018;86(10):86. doi: 10.1128/iai.00567-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [38].Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33(6):479–492. doi: 10.1016/j.semnephrol.2013.08.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [39].Jia L, Luo H, Li L, et al. Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/Staphylococcus aureus coinfection. Signal Transduct Target Ther. 2023;8(1). doi: 10.1038/s41392-023-01714-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- [40].Pedersen ML, Pedersen DV, Winkler MBL, et al. Nanobody‐mediated complement activation to kill HIV‐infected cells. EMBO Mol Med. 2023;15(4):15. doi: 10.15252/emmm.202216422 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [41].Wang H, van de Bovenkamp FS, Dijkstra DJ, et al. Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators. Front Immunol. 2024;15:15. doi: 10.3389/fimmu.2024.1288597 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [42].Mastellos DC, Hajishengallis G, Lambris JD. A guide to complement biology, pathology and therapeutic opportunity. Nat Rev Immunol. 2024;24(2):118–141. doi: 10.1038/s41577-023-00926-1 [DOI] [PubMed] [Google Scholar]
- [43].Dempsey PW, Allison MED, Akkaraju S, et al. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996;271(5247):348–350. doi: 10.1126/science.271.5247.348 [DOI] [PubMed] [Google Scholar]
- [44].Carroll MC. Complement and humoral immunity. Vaccine. 2008;26:I28–I33. doi: 10.1016/j.vaccine.2008.11.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [45].West EE, Kolev M, Kemper C. Complement and the regulation of T cell responses. Annu Rev Immunol. 2018;36(1):309–338. doi: 10.1146/annurev-immunol-042617-053245 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [46].Doorduijn DJ, Rooijakkers SHM, Heesterbeek DAC. How the membrane attack complex damages the bacterial cell envelope and kills Gram‐negative bacteria. Bioessays. 2019;41(10):41. doi: 10.1002/bies.201900074 [DOI] [PubMed] [Google Scholar]
- [47].Dunkelberger JR, Song W-C. Complement and its role in innate and adaptive immune responses. Cell Res. 2009;20(1):34–50. doi: 10.1038/cr.2009.139 [DOI] [PubMed] [Google Scholar]
- [48].Barnum SR, Bubeck D, Schein TN. Soluble membrane attack complex: biochemistry and immunobiology. Front Immunol. 2020;11:11. doi: 10.3389/fimmu.2020.585108 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [49].Ostrycharz E, Hukowska-Szematowicz B. New insights into the role of the complement system in human viral diseases. Biomolecules. 2022:12. doi: 10.3390/biom12020226 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [50].Heesterbeek DAC, Bardoel BW, Parsons ES, et al. Bacterial killing by complement requires membrane attack complex formation via surface‐bound C5 convertases. Embo J. 2019;38(4):38. doi: 10.15252/embj.201899852 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [51].Ward CK, Inzana TJ. Resistance of Actinobacillus pleuropneumoniae to bactericidal antibody and complement is mediated by capsular polysaccharide and blocking antibody specific for lipopolysaccharide. J Immunol. 1994;153(5):2110–2121. doi: 10.1084/jem.180.3.1177 [DOI] [PubMed] [Google Scholar]
- [52].Zhu J, Abruzzo AR, Wu C, et al. Effects of capsular polysaccharide amount on pneumococcal-host interactions. PLOS Pathog. 2023;19:e1011509. doi: 10.1371/journal.ppat.1011509 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [53].Vandendriessche S, Cambier S, Proost P, et al. Complement receptors and their role in leukocyte recruitment and phagocytosis. Front Cell Dev Biol. 2021;9:9. doi: 10.3389/fcell.2021.624025 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [54].Helmy KY, Katschke KJ, Gorgani NN, et al. Crig: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell. 2006;124(5):915–927. doi: 10.1016/j.cell.2005.12.039 [DOI] [PubMed] [Google Scholar]
- [55].Liu G, Fu Y, Yosri M, et al. Crig plays an essential role in intravascular clearance of bloodborne parasites by interacting with complement. Proc Natl Acad Sci. 2019;116(48):24214–24220. doi: 10.1073/pnas.1913443116 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [56].Zeng Z, Surewaard BJ, Wong CY, et al. Crig functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne Gram-positive bacteria. Cell Host Microbe. 2016;20(1):99–106. doi: 10.1016/j.chom.2016.06.002 [DOI] [PubMed] [Google Scholar]
- [57].Kim KH, Choi BK, Kim YH, et al. Extracellular stimulation of VSIG4/complement receptor Ig suppresses intracellular bacterial infection by inducing autophagy. Autophagy. 2016;12(9):1647–1659. doi: 10.1080/15548627.2016.1196314 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [58].Hasegawa M, Yada S, Liu M, et al. Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. Immunity. 2014;41(4):620–632. doi: 10.1016/j.immuni.2014.09.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [59].Wang Y, Liu W, Xu Y, et al. Revealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins. Nat Chem Biol. 2023;19(11):1351–1360. doi: 10.1038/s41589-023-01339-w [DOI] [PubMed] [Google Scholar]
- [60].West EE, Afzali B, Kemper C. Unexpected roles for intracellular complement in the regulation of Th1 responses. Adv Immunol. 2018:35–70. [DOI] [PubMed] [Google Scholar]
- [61].Dahmani M, Zhu JC, Cook JH, et al. Anaphylatoxin signaling activates macrophages to control intracellular rickettsia proliferation. Microbiol spectr. 2023;11(6):e0253823. doi: 10.1128/spectrum.02538-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [62].Asgari E, Le Friec G, Yamamoto H, et al. C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. 2013;122(20):3473–3481. doi: 10.1182/blood-2013-05-502229 [DOI] [PubMed] [Google Scholar]
- [63].Riley Sean P, Fish AI, Del Piero F, et al. Immunity against the obligate intracellular bacterial pathogen Rickettsia australis requires a functional complement system. Infect Immun. 2018;86(6): doi: 10.1128/iai.00139-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [64].Gogoi D, Yu H, Casey M, et al. Monocyte NLRP3 inflammasome and interleukin-1β activation modulated by alpha-1 antitrypsin therapy in deficient individuals. Thorax. 2024;79(9):822–833. doi: 10.1136/thorax-2023-221071 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [65].Khameneh HJ, Ho AWS, Laudisi F, et al. C5a regulates IL-1β production and leukocyte recruitment in a murine model of monosodium urate crystal-induced peritonitis. Front Pharmacol. 2017;8:8. doi: 10.3389/fphar.2017.00010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [66].Liszewski MK, Kolev M, Le Friec G, et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. 2013;39(6):1143–1157. doi: 10.1016/j.immuni.2013.10.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [67].West EE, Kemper C. Complosome — the intracellular complement system. Nat Rev Nephrol. 2023;19(7):426–439. doi: 10.1038/s41581-023-00704-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [68].Xiao MT, Ellsworth CR, Qin X. Emerging role of complement in COVID-19 and other respiratory virus diseases. Cellular Mol Life Sci. 2024;81(1):81. doi: 10.1007/s00018-024-05157-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [69].Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol. 1995;13(1):127–149. doi: 10.1146/annurev.iy.13.040195.001015 [DOI] [PubMed] [Google Scholar]
- [70].Fischer MB, Goerg S, Shen LM, et al. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science. 1998;280(5363):582–585. doi: 10.1126/science.280.5363.582 [DOI] [PubMed] [Google Scholar]
- [71].Qi X, Fang Z, Meng L, et al. The C3d-fused porcine circovirus type 2d virus-like particle induced early and enhanced immune response and protected pigs against challenge. Vet microbiol. 2024;299:110305. doi: 10.1016/j.vetmic.2024.110305 [DOI] [PubMed] [Google Scholar]
- [72].Kolev M, West EE, Kunz N, et al. Diapedesis-induced integrin signaling via LFA-1 facilitates tissue immunity by inducing intrinsic complement C3 expression in immune cells. Immunity. 2020;52(3):513–527.e8. doi: 10.1016/j.immuni.2020.02.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [73].Manfred K, Abel B, Gallimore A, et al. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med. 2002;8(4):373–378. doi: 10.1038/nm0402-373 [DOI] [PubMed] [Google Scholar]
- [74].O’Brien KB, Morrison TE, Dundore DY, et al. A protective role for complement C3 protein during pandemic 2009 H1N1 and H5N1 influenza A virus infection. PLOS ONE. 2011;6(3):6. doi: 10.1371/journal.pone.0017377 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [75].Rattan A, Pawar SD, Nawadkar R, et al. Synergy between the classical and alternative pathways of complement is essential for conferring effective protection against the pandemic influenza A(H1N1) 2009 virus infection. PLOS Pathog. 2017;13(3):13. doi: 10.1371/journal.ppat.1006248 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [76].Desai JV, Kumar D, Freiwald T, et al. C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection. Cell. 2023;186(13):2802–2822.e22. doi: 10.1016/j.cell.2023.04.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [77].Loh JMS, Aghababa H, Proft T. Eluding the immune system’s frontline defense: secreted complement evasion factors of pathogenic Gram-positive cocci. Microbiol Res. 2023;277:277. doi: 10.1016/j.micres.2023.127512 [DOI] [PubMed] [Google Scholar]
- [78].Jain M, Teçza M, Kagawa TF, et al. Exosite binding modulates the specificity of the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease. Comput Struct Biotechnol J. 2022;20:4860–4869. doi: 10.1016/j.csbj.2022.08.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [79].Fernández FJ, Gómez S, Vega MC. Pathogens’ toolbox to manipulate human complement. Semin Cell Dev Biol. 2019;85:98–109. doi: 10.1016/j.semcdb.2017.12.001 [DOI] [PubMed] [Google Scholar]
- [80].Kagawa TF, O’Connell MR, Mouat P, et al. Model for substrate interactions in C5a peptidase from streptococcus pyogenes: a 1.9 Å crystal structure of the active form of ScpA. J Mol Biol. 2009;386(3):754–772. doi: 10.1016/j.jmb.2008.12.074 [DOI] [PubMed] [Google Scholar]
- [81].Dasari P, Nordengrün M, Vilhena C, et al. The protease SplB of Staphylococcus aureus targets host complement components and inhibits complement-mediated bacterial opsonophagocytosis. J Bacteriol. 2022;204:e0018421. doi: 10.1128/jb.00184-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [82].Laabei M, Ermert D. Catch me if you can: Streptococcus pyogenes complement evasion strategies. J Innate Immun. 2019;11(1):3–12. doi: 10.1159/000492944 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [83].Ruest MK, Dennis JJ. The exploration of complement-resistance mechanisms of pathogenic Gram-negative bacteria to support the development of novel therapeutics. Pathogens. 2022;11(8):11. doi: 10.3390/pathogens11080931 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [84].Freire CA, Silva RM, Ruiz RC, et al. Secreted autotransporter toxin (Sat) mediates innate immune system evasion. Front Immunol. 2022:13. doi: 10.3389/fimmu.2022.844878 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [85].Amamura TA, Fraga TR, Vasconcellos SA, et al. Pathogenic leptospira secreted proteases target the membrane attack complex: a potential role for thermolysin in complement inhibition. Front microbiol. 2017;8:8. doi: 10.3389/fmicb.2017.00958 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [86].Laarman AJ, Bardoel BW, Ruyken M, et al. Pseudomonas aeruginosa alkaline protease blocks complement activation via the classical and lectin pathways. J Immunol. 2012;188(1):386–393. doi: 10.4049/jimmunol.1102162 [DOI] [PubMed] [Google Scholar]
- [87].Hastings Cody J, Syed Shazrah S, Marques Cláudia Nogueira H. Subversion of the complement system by Pseudomonas aeruginosa. J Bacteriol. 2023;205(8):e00018–00023. doi: 10.1128/jb.00018-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [88].Kessler E. The secreted aminopeptidase of Pseudomonas aeruginosa (PaAP). Int J Mol Sci. 2024;25(15):8444. doi: 10.3390/ijms25158444 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [89].Gil E, Noursadeghi M, Brown JS. Streptococcus pneumoniae interactions with the complement system. Front Cell Infect microbiol. 2022;12:12. doi: 10.3389/fcimb.2022.929483 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [90].Fernie-King BA, Seilly DJ, Willers C, et al. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology. 2001. doi: 10.1046/j.1365-2567.2001.01249.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- [91].Pence MA, Rooijakkers SHM, Cogen AL, et al. Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A streptococcus. J Innate Immun. 2010. doi: 10.1159/000317672 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [92].Blom AM, Bergmann S, Fulde M, et al. Streptococcus pneumoniae phosphoglycerate kinase is a novel complement inhibitor affecting the membrane attack complex formation. J Biol Chem. 2014;289(47):32499–32511. doi: 10.1074/jbc.M114.610212 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [93].Schindler MKH, Schütz MS, Mühlenkamp MC, et al. Yersinia enterocolitica YadA mediates complement evasion by recruitment and inactivation of C3 products. J Immunol. 2012;189(10):4900–4908. doi: 10.4049/jimmunol.1201383 [DOI] [PubMed] [Google Scholar]
- [94].Woehl JL, Stapels DAC, Garcia BL, et al. The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase. J Immunol. 2014;193:6161–6171. doi: 10.4049/jimmunol.1401600 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [95].Nemani VP, Blom AM, Villoutreix BO, et al. A novel interaction of outer membrane protein A with C4b binding protein mediates serum resistance of Escherichia coli K1. J Immunol. 2002;169(11):6352–6360. doi: 10.4049/jimmunol.169.11.6352 [DOI] [PubMed] [Google Scholar]
- [96].Wooster DG, Maruvada R, Blom AM, et al. Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by promoting C4bp-mediated C3b and C4b degradation. Immunology. 2006;117(4):482–493. doi: 10.1111/j.1365-2567.2006.02323.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- [97].Liu YF, Yan JJ, Lei HY, et al. Loss of outer membrane protein C in Escherichia coli contributes to both antibiotic resistance and escaping antibody-dependent bactericidal activity. Infect Immun. 2012;80:1815–1822. doi: 10.1128/iai.06395-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [98].Freitag T, Squires RA, Schmid J, et al. Feline uropathogenic Escherichia coli from Great Britain and New Zealand have dissimilar virulence factor genotypes. Vet microbiol. 2005;106(1–2):79–86. doi: 10.1016/j.vetmic.2004.11.014 [DOI] [PubMed] [Google Scholar]
- [99].Pramoonjago P, Kaneko M, Kinoshita T, et al. Role of TraT protein, an anticomplementary protein produced in Escherichia coli by R100 factor, in serum resistance. J Immunol. 1992;148(3): 827–836. [PubMed] [Google Scholar]
- [100].Li M, Wu M, Sun Y, et al. Edwardsiella tarda trat is an anti-complement factor and a cellular infection promoter. Commun Biol. 2022;5(1):5. doi: 10.1038/s42003-022-03587-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [101].W-Y X, Y-J L, Fan C. Different loci and mRNA copy number of the increased serum survival gene of Escherichia coli. Can J microbiol. 2017;64(2):147–154. doi: 10.1139/cjm-2017-0363 [DOI] [PubMed] [Google Scholar]
- [102].Fan C, Wang Y, Wang Y, et al. Relationship between ISS gene and the virulence of avian Escherichia coli. Chin Vet Sci. 2010;40(1): 55–60 doi: 10.16656/j.issn.1673-4696.2010.01.003 [DOI] [Google Scholar]
- [103].Lee SK, Crosnier C, Valenzuela-Leon PC, et al. Complement receptor 1 is the human erythrocyte receptor for plasmodium vivax erythrocyte binding protein. Proc Natl Acad Sci USA. 2024;121(5):e2316304121. doi: 10.1073/pnas.2316304121 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [104].Smith Nicholas A, Coleman CB, Gewurz BE, et al. Cd21 (complement receptor 2) is the receptor for Epstein-Barr virus entry into T cells. J virol. 2020;94(11): doi: 10.1128/jvi.00428-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [105].Poole J, Day CJ, Haselhorst T, et al. Repurposed drugs that block the gonococcus-complement receptor 3 interaction can prevent and cure gonococcal infection of primary human cervical epithelial cells. MBio. 2020;11(2):11. doi: 10.1128/mBio.03046-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [106].Jennings MP, Jen FE-C, Roddam LF, et al. Neisseria gonorrhoeae pilin glycan contributes to CR3 activation during challenge of primary cervical epithelial cells. Cell microbiol. 2011;13(6):885–896. doi: 10.1111/j.1462-5822.2011.01586.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- [107].Day CJ, Hardison RL, Spillings BL, et al. Complement receptor 3 mediates HIV-1 transcytosis across an intact cervical epithelial cell barrier: new insight into HIV transmission in women. MBio. 2022;13(1):e02177–02121. doi: 10.1128/mbio.02177-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [108].Bordron A, Bagacean C, Tempescul A, et al. Complement system: a neglected pathway in immunotherapy. Clin Rev Allergy Immunol. 2019;58(2):155–171. doi: 10.1007/s12016-019-08741-0 [DOI] [PubMed] [Google Scholar]
- [109].Singh B, Su Y-C, Riesbeck K. Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol microbiol. 2010;78(3):545–560. doi: 10.1111/j.1365-2958.2010.07373.x [DOI] [PubMed] [Google Scholar]
- [110].Hovingh ES, van den Broek B, Jongerius I. Hijacking complement regulatory proteins for bacterial immune evasion. Front microbiol. 2016;7:7. doi: 10.3389/fmicb.2016.02004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [111].Grover SP, Kawano T, Wan J, et al. C1 inhibitor deficiency enhances contact pathway–mediated activation of coagulation and venous thrombosis. Blood. 2023;141:2390–2401. doi: 10.1182/blood.2022018849 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [112].Jongerius I, Schuijt TJ, Mooi FR, et al. Complement evasion by Bordetella pertussis: implications for improving current vaccines. J Mol Med (berl). 2015;93(4):395–402. doi: 10.1007/s00109-015-1259-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [113].Brookes C, Freire-Martin I, Cavell B, et al. Bordetella pertussis isolates vary in their interactions with human complement components. Emerg Microbes Infect. 2018;7:81. doi: 10.1038/s41426-018-0084-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [114].Wu J, Wu Y-Q, Ricklin D, et al. Structure of complement fragment C3b–factor H and implications for host protection by complement regulators. Nat Immunol. 2009;10(7):728–733. doi: 10.1038/ni.1755 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [115].Seib KL, Scarselli M, Comanducci M, et al. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. Expert Rev Vaccines. 2015;14:841–859. doi: 10.1586/14760584.2015.1016915 [DOI] [PubMed] [Google Scholar]
- [116].Yee W-X, Barnes G, Lavender H, et al. Meningococcal factor H-binding protein: implications for disease susceptibility, virulence, and vaccines. Trends microbiol. 2023;31(8):805–815. doi: 10.1016/j.tim.2023.02.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [117].Lewis Lisa A, Rice Peter A, Ram S. Role of gonococcal neisserial surface protein a (NspA) in serum resistance and comparison of its factor H binding properties with those of its meningococcal counterpart. Infect Immun. 2019;87: doi: 10.1128/iai.00658-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [118].Yu Y, Wang J, Han R, et al. Mycoplasma hyopneumoniae evades complement activation by binding to factor H via elongation factor thermo unstable (EF-Tu). Virulence. 2020;11(1):1059–1074. doi: 10.1080/21505594.2020.1806664 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [119].Meri T, Amdahl H, Lehtinen MJ, et al. Microbes bind complement inhibitor factor H via a common site. PLOS Pathog. 2013;9(4):e1003308. doi: 10.1371/journal.ppat.1003308 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [120].Kenedy MR, Akins DR, Bliska JB. The OspE-related proteins inhibit complement deposition and enhance serum resistance of Borrelia burgdorferi, the Lyme disease spirochete. Infect Immun. 2011;79(4):1451–1457. doi: 10.1128/iai.01274-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [121].Coburn J, Kogan K, Haapasalo K, et al. Mechanism of borrelia immune evasion by FhbA-related proteins. PLOS Pathog. 2022;18(3):18. doi: 10.1371/journal.ppat.1010338 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [122].Kunert A, Losse J, Gruszin C, et al. Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor tuf is a factor H and plasminogen binding protein. J Immunol. 2007;179(5):2979–2988. doi: 10.4049/jimmunol.179.5.2979 [DOI] [PubMed] [Google Scholar]
- [123].Ermert D, Blom AM. C4b-binding protein: the good, the bad and the deadly. Novel functions of an old friend. Immunol Lett. 2016;169:82–92. doi: 10.1016/j.imlet.2015.11.014 [DOI] [PubMed] [Google Scholar]
- [124].Tseng YT, Wang SW, Kim KS, et al. Nlpi facilitates deposition of C4BP on Escherichia coli by blocking classical complement-mediated killing, which results in high-level bacteremia. Infect Immun. 2012;80(10):3669–3678. doi: 10.1128/iai.00320-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [125].Jarva H, Ram S, Vogel U, et al. Binding of the complement inhibitor C4bp to serogroup B neisseria meningitidis. J Immunol. 2005;174:6299–6307. doi: 10.4049/jimmunol.174.10.6299 [DOI] [PubMed] [Google Scholar]
- [126].Dieudonné-Vatran A, Krentz S, Blom AM, et al. Clinical isolates of streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion. J Immunol. 2009;182(12):7865–7877. doi: 10.4049/jimmunol.0802376 [DOI] [PubMed] [Google Scholar]
- [127].Kolesiński P, McGowan M, Botteaux A, et al. Conservation of C4BP-binding sequence patterns in Streptococcus pyogenes M and Enn proteins. J Biol Chem. 2024;300(7):107478. doi: 10.1016/j.jbc.2024.107478 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [128].Pellegrini A, Pietrocola G. Recruitment of vitronectin by bacterial pathogens: a comprehensive overview. Microorganisms. 2024:12. doi: 10.3390/microorganisms12071385 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [129].Riley SP, Patterson JL, Nava S, et al. Pathogenic rickettsia species acquire vitronectin from human serum to promote resistance to complement-mediated killing. Cell microbiol. 2014;16:849–861. doi: 10.1111/cmi.12243 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [130].Fish AI, Riley SP, Singh B, et al. The Rickettsia conorii Adr1 interacts with the C-terminus of human vitronectin in a salt-sensitive manner. Front Cell Infect microbiol. 2017;7:61. doi: 10.3389/fcimb.2017.00061 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [131].Garza DA, Riley SP, Martinez JJ. Expression of rickettsia Adr2 protein in E. coli is sufficient to promote resistance to complement-mediated killing, but not adherence to mammalian cells. PLOS ONE. 2017;12(6):e0179544. doi: 10.1371/journal.pone.0179544 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [132].Li S, Wang Y, Yang R, et al. Outer membrane protein OMP76 of Riemerella anatipestifer contributes to complement evasion and virulence by binding to duck complement factor vitronectin. Virulence. 2023:14. doi: 10.1080/21505594.2023.2223060 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [133].Conde JN, da Silva EM, Allonso D, et al. Inhibition of the membrane attack complex by dengue virus NS1 through interaction with vitronectin and terminal complement proteins. J virol. 2016;90(21):9570–9581. doi: 10.1128/jvi.00912-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [134].Koelman DLH, Brouwer MC, van de Beek D. Targeting the complement system in bacterial meningitis. Brain. 2019;142(11):3325–3337. doi: 10.1093/brain/awz222 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [135].Syed I, Wooten RM. Interactions between pathogenic Burkholderia and the complement system: a review of potential immune evasion mechanisms. Front Cell Infect microbiol. 2021;11:701362. doi: 10.3389/fcimb.2021.701362 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [136].Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019;18(9):707–729. doi: 10.1038/s41573-019-0031-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [137].Meri S, Jördens M, Jarva H. Microbial complement inhibitors as vaccines. Vaccine. 2008;26:I113–I117. doi: 10.1016/j.vaccine.2008.11.058 [DOI] [PubMed] [Google Scholar]
- [138].McIntyre PB, O’Brien KL, Greenwood B, et al. Effect of vaccines on bacterial meningitis worldwide. Lancet. 2012;380:1703–1711. doi: 10.1016/S0140-6736(12)61187-8 [DOI] [PubMed] [Google Scholar]
- [139].Rappuoli R, Pizza M, Masignani V, et al. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17(12):1111–1121. doi: 10.1080/14760584.2018.1547637 [DOI] [PubMed] [Google Scholar]
- [140].Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388:2775–2782. doi: 10.1016/S0140-6736(16)31921-3 [DOI] [PubMed] [Google Scholar]
- [141].Lewis LA, Ngampasutadol J, Wallace R, et al. The meningococcal vaccine candidate neisserial surface protein a (NspA) binds to factor H and enhances meningococcal resistance to complement. PLOS Pathog. 2010;6(7):e1001027. doi: 10.1371/journal.ppat.1001027 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [142].Schmidt CQ, Smith RJH. Protein therapeutics and their lessons: expect the unexpected when inhibiting the multi‐protein cascade of the complement system. Immunol Rev. 2022;313(1):376–401. doi: 10.1111/imr.13164 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
